AR057769A1 - Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas - Google Patents

Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas

Info

Publication number
AR057769A1
AR057769A1 ARP060103658A ARP060103658A AR057769A1 AR 057769 A1 AR057769 A1 AR 057769A1 AR P060103658 A ARP060103658 A AR P060103658A AR P060103658 A ARP060103658 A AR P060103658A AR 057769 A1 AR057769 A1 AR 057769A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroalkyl
hydrogen
heterocyclyl
heteroaryl
Prior art date
Application number
ARP060103658A
Other languages
English (en)
Inventor
Roland Joseph Billedeau
Nolan James Dewdney
Tobias Gabriel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR057769A1 publication Critical patent/AR057769A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Métodos de utilizacion de los compuestos para el tratamiento de enfermedades mediadas por la MAP quinasa p38 y composiciones farmacéuticas. Reivindicacion 1: Un compuesto con la formula (1) o (2), o una sal farmacéuticamente aceptable de los mismos, en los que: n es de 0 a 4; R1 es fenilo opcionalmente sustituido; R2 es heteroarilo, heterociclilo, -C(=O)-Ra, -CN, -S(O)mRa, -NRbC(=O)-Ra, -O-C(=O)-Ra o -NRbSO2Ra, en el que m es de 0 a 2, Ra es alquilo, heteroalquilo, amino, alquilamino, dialquilamino, hidroxi o alcoxi; y Rb es hidrogeno o alquilo; R3 es hidrogeno o alquilo; R4 es hidrogeno, alquilo, hidroxi, amino, heteroalquilo, heteroalcoxi, heteroalquilamino, heterociclilo, heterociclilalquilo, hidroxicicloalquilo, cicloalquilalquilo, alquilsulfonilo, alquilsulfonamido, arilo, heteroarilo, aralquilo, heteroaralquilo, alcoxi, heteroaralcoxi, -(CHRc) r-C(=O)-Rd, -(CHRc)r-O-C(=O)-Rd, -(CHRc)r-NH-C(=O)-Rd o -SO2-Rd, en lo que: Rc es hidrogeno, alquilo o heteroalquilo; Rd es alquilo, hidroxi, amino, heteroalquilo, arilo, aralquilo, heteroarilo, o heterociclilo; r es de 0 a 4; cada R5 es independientemente alquilo, halo, haloalquilo, alcoxi, haloalcoxi, ciano, nitro, hidroxi, amino, heteroalquilo, heterociclilo, heterociclilalquilo, hidroxicicloalquilo, cicloalquilalquilo, alcoxialquiloxi, arilo, heteroarilo, aralquilo, heteroaralquilo, aralcoxi, heteroaralquiloxi, cianoalcoxi, alquenilalcoxi, alquinilalcoxi, hidroxialquiloxi, hidroxialquilalquinilalcoxi, -(CHRe)s-C(=O)-Rf, -(CHRe)s-O-C(=O)-Rf, -(CHRe)s-NH-C(=O)-Rf o -SO2-Rf, en los que: Re es hidrogeno, alquilo o heteroalquilo; Rf es alquilo, hidroxi, amino, alquilamino, heteroalquilo, arilo, aralquilo, heteroarilo, o heterociclilo; y s es de 0 a 4; X e Y son nitrogeno, o uno de X e Y es nitrogeno y el otro es CRg; en el que: Rg es hidrogeno, alquilo, hidroxi, alcoxi, amino, haloalquilo, ciano, halo, heteroalquilo, C(-O)-Rh o -SO2-Rh, en los que: Rh es hidrogeno o alquilo; uno o dos de D, E y G es nitrogeno, o D, E y G son carbono; W es un enlace, O, S(O)t, CH2 o NRi; en el que t es de 0 a 2; y Ri es hidrogeno, alquilo, heteroalquilo, heterociclilo, hidroxicicloalquilo, -C(-O)-Rj o -SO2- Rj, en el que Rj es alquilo, arilo, aralquilo, heteroarilo, heteroalquilo o heterociclilo; o W y R4 juntos forman ciano; o R4 y Ri junto a los átomos a los que están unidos pueden formar un anillo heterocíclico; A es O, CH2, S(O)u, C(=O), NRk, o CH(ORk), en los que u es de 0 a 2; y Rk es hidrogeno o alquilo.
ARP060103658A 2005-08-25 2006-08-23 Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas AR057769A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71201005P 2005-08-25 2005-08-25

Publications (1)

Publication Number Publication Date
AR057769A1 true AR057769A1 (es) 2007-12-19

Family

ID=37769347

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103658A AR057769A1 (es) 2005-08-25 2006-08-23 Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas

Country Status (13)

Country Link
US (1) US7563799B2 (es)
EP (1) EP1919918A2 (es)
JP (1) JP2009506007A (es)
KR (1) KR101011956B1 (es)
CN (1) CN101243088B (es)
AR (1) AR057769A1 (es)
AU (1) AU2006283941A1 (es)
BR (1) BRPI0615442A2 (es)
CA (1) CA2620105A1 (es)
IL (1) IL189356A0 (es)
MX (1) MX2008002588A (es)
TW (1) TW200744604A (es)
WO (1) WO2007023111A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8220787B2 (en) * 2008-09-19 2012-07-17 Panasonic Corporation Part mounting device
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
BR112014006127A2 (pt) 2011-09-14 2017-04-04 Samumed Llc indazol-3-carboxamidas e sua utilização como inibidores da via de sinalização wnt/b-catenina
US20150038541A1 (en) * 2012-03-19 2015-02-05 Aposignal Bioscience Llc Composition and methods for cell modulation
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
EP2943198B1 (en) 2013-01-08 2019-07-17 Samumed, LLC 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017024015A1 (en) * 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023993A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024025A1 (en) 2015-08-03 2017-02-09 Sunil Kumar Kc 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023988A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
MX2018005696A (es) 2015-11-06 2018-11-09 Samumed Llc Tratamiento de la osteoartritis.
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
JP7076432B2 (ja) 2016-09-09 2022-05-27 インサイト・コーポレイション Ｈｐｋ１調節薬としてのピラゾロピリジン誘導体及びがんの治療のためのその用法
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
EP3528808B1 (en) 2016-10-21 2021-10-06 BioSplice Therapeutics, Inc. Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
JP2019533702A (ja) 2016-11-07 2019-11-21 サミュメッド リミテッド ライアビリティ カンパニー 単回用量の調整済み注射用製剤
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
AU2018346712B2 (en) 2017-10-05 2021-04-01 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
ES2922237T3 (es) 2018-02-20 2022-09-12 Incyte Corp Derivados de N-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de HPK1 para tratar el cáncer
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
EP3856348B1 (en) 2018-09-25 2024-01-03 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
WO2021026180A1 (en) 2019-08-06 2021-02-11 Incyte Corporation Solid forms of an hpk1 inhibitor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821382A (en) 1969-10-28 1974-06-28 Ciba Geigy Corp 5-nitrofuryl derivatives as antibacterial agents
BE758050A (fr) 1969-10-28 1971-04-27 Geigy Ag J R Derives 5-nitro-furyliques et medicaments contenant de tels composes
US3948913A (en) 1971-04-27 1976-04-06 Ciba-Geigy Corporation New 5-nitrofuryl derivatives
US4020072A (en) 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
IT1154024B (it) 1982-09-22 1987-01-21 Lepetit Spa Derivati pridinici e procedimento per la loro produzione
JP3554337B2 (ja) 1996-09-04 2004-08-18 ファイザー・インク インダゾール誘導体、およびホスホジエステラーゼ（ｐｄｅ）タイプ４と腫瘍壊死因子（ｔｎｆ）産生の阻害剤としてのインダゾール誘導体の使用
JP2001521926A (ja) 1997-11-04 2001-11-13 ファイザー・プロダクツ・インク 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換
AU1818400A (en) 1998-11-12 2000-05-29 Eli Lilly And Company Aryloxime linkers in the solid-phase synthesis of 3-aminobenzisoxazoles
DE60115132T2 (de) 2000-04-21 2006-07-06 Pfizer Products Inc., Groton Thyroid-Rezeptorliganden
AU2001264313A1 (en) 2000-06-20 2002-01-02 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
CN1281605C (zh) 2000-12-22 2006-10-25 惠氏公司 作为5－羟色胺－6配基的杂环基－吲唑或氮杂吲唑化合物
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
EP1463742A4 (en) 2001-06-21 2006-05-10 Ariad Pharma Inc NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES
WO2003009852A1 (en) 2001-07-24 2003-02-06 Merck & Co., Inc. Tyrosine kinase inhibitors
ES2309206T3 (es) * 2001-10-02 2008-12-16 Smithkline Beecham Corporation Compuestos quimicos.
WO2003062392A2 (en) 2002-01-18 2003-07-31 Ceretek Llc Methods of treating conditions associated with an edg receptor
TW200302722A (en) 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
ATE410429T1 (de) 2002-03-07 2008-10-15 Hoffmann La Roche Bicyclische pyridin- und pyrimidininhibitoren von p38-kinase
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2004078116A2 (en) 2003-03-03 2004-09-16 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
BRPI0418112A (pt) * 2003-12-23 2007-04-17 Novartis Ag inibidores de p-38 quinase bicìclico heterocìclicos
CN1926139A (zh) * 2004-02-27 2007-03-07 霍夫曼-拉罗奇有限公司 稠合吡唑衍生物
KR100844864B1 (ko) * 2004-02-27 2008-07-09 에프. 호프만-라 로슈 아게 헤테로아릴-융합 피라졸로 유도체
US7405220B2 (en) * 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
GB0427604D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR101011956B1 (ko) 2011-01-31
WO2007023111A2 (en) 2007-03-01
JP2009506007A (ja) 2009-02-12
TW200744604A (en) 2007-12-16
MX2008002588A (es) 2008-03-18
AU2006283941A1 (en) 2007-03-01
US7563799B2 (en) 2009-07-21
US20070049598A1 (en) 2007-03-01
IL189356A0 (en) 2008-06-05
BRPI0615442A2 (pt) 2011-05-17
CN101243088A (zh) 2008-08-13
WO2007023111A3 (en) 2007-05-18
KR20080040731A (ko) 2008-05-08
EP1919918A2 (en) 2008-05-14
CA2620105A1 (en) 2007-03-01
CN101243088B (zh) 2011-06-29

Similar Documents

Publication Publication Date Title
AR057769A1 (es) Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas
ES2834027T3 (es) Compuestos de N-pirrolidinil, N'-pirazolil-urea como inhibidores de TrkA quinasa
RU2008116844A (ru) Ацилированные производные спиропиперидина как модуляторы рецептора меланокортина-4
PE20221253A1 (es) Inhibidores de pequenas moleculas de mutante g12c de kras
AR048302A1 (es) DERIVADOS DE PIRAZOLO-PIRIMIDINA, DE PIRAZOLO-PIRIMIDINONA, DE PIRAZOLO-PIRIDINA Y DE PIRAZOLO-PIRAZINA FUSIONADOS, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA PREPARACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA CINASA P38
AR057770A1 (es) Inhibidores de la p38-map-quinasa y composicion farmaceutica
AR051461A1 (es) Compuesto de pirazolo[1,5-a]pirimidin-7-il-amina forma poliformica 1 de [3-(4-metoxi-2-metil-fenil)-2,5-dimetil-pirazolo[1,5-a]pirimidin-7-il]-[(s)-1-(3-metil-[1,2,4]oxadiazol-5-il)-propil]-amina, composicion farmaceutica que lo comprende y su uso para prepararla
AR038000A1 (es) Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento
AR044045A1 (es) Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion
AR038863A1 (es) Uso de un inhibidor de garft y/o de aicarft y de un agente antitoxico para preparar un medicamento para destruir selectivamente celulas mtap-deficientes de un mamifero
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR044011A1 (es) Antagonistas de mchr1 heterociclicos
MX2007007428A (es) Compuestos heterociclicos, antagonistas de ccr2b.
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
AR070366A1 (es) Inhibidores del virus de la hepatitis c
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
BR122021002178B1 (pt) Uso de compostos inibidores de pirimidinil tirosina quinase
AR054000A1 (es) Compuesto de n-(fenilpropil)-sulfonamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, producto de combinacion que comprende dicho compuesto y metodo para prepararlo
AR067412A1 (es) Moduladores de propiedades farmaceuticas de productos terapeuticos
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
AR050084A1 (es) Derivados de bencimidazolona como inhibidores de hsp90
RU2009118963A (ru) Пурины в качестве ингибиторов ркс-тета

Legal Events

Date Code Title Description
FA Abandonment or withdrawal